Literature DB >> 30848176

Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions.

Jonathan González-García1, Fernando Gutiérrez-Nicolás2, Gloria Julia Nazco-Casariego3, María Micaela Viña-Romero4.   

Abstract

OBJECTIVE: The present work analyzed the stability of trastuzumab  concentrations in blood and plasma samples stored at 4 °C and -20 °C.
METHOD: Blood samples of patients treated with trastuzumab (Herceptin ®)  were analyzed. Stability of trastuzumab was analyzed under different conditions: whole blood stored at 4 °C during 72 hours, blood  plasma stored at 4 °C during 120 hours and blood plasma stored at -20 °C during 365 days.
RESULTS: In whole blood trastuzumab concentration at 72 hours was 99.01 ± 0.02%, and in plasma samples at 120 hours it was 98.6 ± 2.0%. The  concentration of trastuzumab was 95.22 ± 3.20% after 12 months' storage  at -20 ºC.
CONCLUSIONS: The concentration of trastuzumab remains stable for at least  72 hours in whole blood stored at 4 °C, five days in plasma stored at 4 °C  and one year in plasma stored at -20 °C. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30848176     DOI: 10.7399/fh.11110

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  2 in total

Review 1.  Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.

Authors:  Nandeeta Samad; Temitayo Eniola Sodunke; Hasan Al Banna; Ashmita Sapkota; Aneeka Nawar Fatema; Katia Iskandar; Dilshad Jahan; Timothy Craig Hardcastle; Tanzina Nusrat; Tajkera Sultana Chowdhury; Mainul Haque
Journal:  Risk Manag Healthc Policy       Date:  2020-11-23

2.  Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks.

Authors:  Daniel Stadlbauer; Ian Baine; Fatima Amanat; Kaijun Jiang; Kimberly Lally; Florian Krammer; Jeffrey S Jhang; Suzanne A Arinsburg
Journal:  Transfusion       Date:  2020-09-23       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.